Hay fever: One in three people showing ‘potentially severe allergies’
Hay fever is a seasonal woe for millions of people around the globe, but there is evidence that warmer climates are intensifying the threat to human health. According to new
Hay fever is a seasonal woe for millions of people around the globe, but there is evidence that warmer climates are intensifying the threat to human health. According to new
Europe’s biggest free-from event returns to London – and it’s free! The Allergy & Free From Show London is back and bigger than ever in their new home at ExCeL
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, stated today that will share positive new data from across its research portfolio at the joint WAO
The Met Office is forecasting five days of high pollen levels for Bristol this week. The service has a five-day pollen forecast for every region in the country and, looking at the
Coronavirus cases rose in late March, around the same time that many people began to experience seasonal allergy symptoms. How can you tell the difference between hay fever and coronavirus?
Got itchy eyes? Sneezing? Feeling bunged up? That could be because hayfever season has already started, with high tree pollen levels forecast this week. Kleenex now has a forecast that
The arrival of spring brings with it allergy season for millions of people around the world as flowering trees and plants release allergy-inducing pollens. Now, thanks to climate change, allergy
An urgent warning has been issued to millions of hay fever sufferers across the UK as the weather starts to warm up. Temperatures are set to skyrocket over the coming
A phase 2 trial of Allergy Therapeutics’ grass pollen candidate met its primary endpoint of showing a dose-response relationship. With the trial also establishing a recommended dose of the short-course subcutaneous allergen-specific
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head